Palisade Bio (PALI) Net Equity Issued and Repurchased (2010 - 2026)

Palisade Bio (PALI) has 14 years of Net Equity Issued and Repurchased data on file, last reported at $3.2 million in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $131.5 million, a 1458.61% increase from a year earlier, with the FY2025 full-year figure at $128.2 million, up 1420.08% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $3.2 million, down from $128.2 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for PALI reached as high as $128.2 million in Q4 2025 and fell as low as $1.7 million in Q3 2023.
• Historically, Net Equity Issued and Repurchased has averaged $18.2 million across 5 years, with a median of $4.0 million in 2024.
• Across the five-year window, Net Equity Issued and Repurchased plunged 86.23% in 2023 and surged 2791.07% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $12.6 million in 2022, then plunged by 86.23% to $1.7 million in 2023, then surged by 155.18% to $4.4 million in 2024, then jumped by 2791.07% to $128.2 million in 2025, then tumbled by 97.47% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $3.2 million in Q1 2026, $128.2 million in Q4 2025, and $4.4 million in Q4 2024.